ArticleCancer gene therapy2013
Expression of the coxsackie adenovirus receptor in neuroendocrine lung cancers and its implications for oncolytic adenoviral infection.
Article in Cancer gene therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 26 citations in OpenAlex.
- Oncolytic viruses: advanced strategies in cancer therapy.Signal transduction and targeted therapy · 2026Review
- Receptors and Host Factors for Enterovirus Infection: Implications for Cancer Therapy.Cancers · 2024Review
- CAR expression in invasive breast carcinoma and its effect on adenovirus transduction efficiency.Breast cancer research : BCR · 2024Article
- A Local and Abscopal Effect Observed with Liposomal Encapsulation of Intratumorally Injected Oncolytic Adenoviral Therapy.Cancers · 2023Article
- Signal pathways and precision therapy of small-cell lung cancer.Signal transduction and targeted therapy · 2022Review
- Histone modifiers at the crossroads of oncolytic and oncogenic viruses.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Review
- CAR Co-Operates With Integrins to Promote Lung Cancer Cell Adhesion and Invasion.Frontiers in oncology · 2022Article
- Evolving Role of Oncolytic Virotherapy: Challenges and Prospects in Clinical Practice.JCO precision oncology · 2021Review
- Co-Expression of Coxsackievirus/Adenovirus Receptors and Desmoglein 2 in Lung Adenocarcinoma: A Comprehensive Analysis of Bioinformatics and Tissue Microarrays.Journal of clinical medicine · 2020Article
- Generation and evaluation of a chimeric antibody against coxsackievirus and adenovirus receptor for cancer therapy.Cancer science · 2019Article
- Expression of coxsackie and adenovirus receptor is correlated with inferior prognosis in liver cancer patients.Oncology letters · 2019Article
- Oncolytic virus immunotherapies in ovarian cancer: moving beyond adenoviruses.Porto biomedical journal · 2018Article
- A novel monoclonal antibody targeting coxsackie virus and adenovirus receptor inhibits tumor growth in vivo.Scientific reports · 2017Article
- Potential for evolution of complex defense strategies in a multi-scale model of virus-host coevolution.BMC evolutionary biology · 2016Article
- Loss of coxsackie and adenovirus receptor expression in human colorectal cancer: A potential impact on the efficacy of adenovirus-mediated gene therapy in Chinese Han population.Molecular medicine reports · 2016Article
- Presence of the coxsackievirus and adenovirus receptor (CAR) in human neoplasms: a multitumour array analysis.British journal of cancer · 2013Article
- Effects of heat stress on the expression of the coxsackievirus and adenovirus receptor in mouse skin keratinocytes.Experimental and therapeutic medicine · 2013Article
- Optical detection and virotherapy of live metastatic tumor cells in body fluids with vaccinia strains.PloS one · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coxsackie adenovirus receptor (CAR) is the primary receptor to which oncolytic adenoviruses have to bind for internalization and viral replication. A total of 171 neuroendocrine lung tumors in form of multitissue arrays have been analyzed resulting in a positivity of 112 cases (65.5%). Immunostaining correlated statistically significant with histopathology and development of recurrence. The subtype small cell lung cancer (SCLC) showed the highest CAR expression (77.6%), moreover the CAR level was correlated to the disease-free survival. Further, high CAR expression level in SCLC cell lines was found in vitro and in vivo when cell lines had been transplanted into immunodeficient mice. A correlation between CAR expression in the primary tumors and metastases development in the tumor model underlined the clinical relevance. Cell lines with high CAR level showed a high infectivity when infected with a replication-deficient adenovirus. Low levels of CAR expression in SCLC could be upregulated with Trichostatin A, a histone deacetylase inhibitor. As a result of the unaltered poor prognosis of SCLC and its high CAR expression it seems to be the perfect candidate for oncolytic therapy. With our clinically relevant tumor model, we show that xenograft experiments are warrant to test the efficiency of oncolytic adenoviral therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.